ID   TERA1_CAEEL             Reviewed;         809 AA.
AC   P54811;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   18-JUN-2025, entry version 182.
DE   RecName: Full=Transitional endoplasmic reticulum ATPase homolog 1 {ECO:0000305};
DE            EC=3.6.4.6 {ECO:0000269|PubMed:18782221, ECO:0000269|PubMed:18854144, ECO:0000269|PubMed:21454554};
DE   AltName: Full=Cell division cycle-related protein 48.1 {ECO:0000312|WormBase:C06A1.1};
DE   AltName: Full=p97/CDC48 homolog 1 {ECO:0000305};
GN   Name=cdc-48.1 {ECO:0000312|WormBase:C06A1.1};
GN   ORFNames=C06A1.1 {ECO:0000312|WormBase:C06A1.1};
OS   Caenorhabditis elegans.
OC   Eukaryota; Metazoa; Ecdysozoa; Nematoda; Chromadorea; Rhabditida;
OC   Rhabditina; Rhabditomorpha; Rhabditoidea; Rhabditidae; Peloderinae;
OC   Caenorhabditis.
OX   NCBI_TaxID=6239;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Bristol N2;
RX   PubMed=9851916; DOI=10.1126/science.282.5396.2012;
RG   The C. elegans sequencing consortium;
RT   "Genome sequence of the nematode C. elegans: a platform for investigating
RT   biology.";
RL   Science 282:2012-2018(1998).
RN   [2]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=15716356; DOI=10.1091/mbc.e04-08-0726;
RA   Poteryaev D., Squirrell J.M., Campbell J.M., White J.G., Spang A.;
RT   "Involvement of the actin cytoskeleton and homotypic membrane fusion in ER
RT   dynamics in Caenorhabditis elegans.";
RL   Mol. Biol. Cell 16:2139-2153(2005).
RN   [3]
RP   TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=16701565; DOI=10.1016/j.bbrc.2006.04.160;
RA   Yamauchi S., Yamanaka K., Ogura T.;
RT   "Comparative analysis of expression of two p97 homologues in Caenorhabditis
RT   elegans.";
RL   Biochem. Biophys. Res. Commun. 345:746-753(2006).
RN   [4]
RP   FUNCTION, INTERACTION WITH CDC-48.2; UFD-1 AND UBXN-1, AND DISRUPTION
RP   PHENOTYPE.
RX   PubMed=16647269; DOI=10.1016/j.jsb.2006.02.015;
RA   Mouysset J., Kaehler C., Hoppe T.;
RT   "A conserved role of Caenorhabditis elegans CDC-48 in ER-associated protein
RT   degradation.";
RL   J. Struct. Biol. 156:41-49(2006).
RN   [5]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=17512499; DOI=10.1016/j.bbrc.2007.05.022;
RA   Sasagawa Y., Yamanaka K., Nishikori S., Ogura T.;
RT   "Caenorhabditis elegans p97/CDC-48 is crucial for progression of meiosis
RT   I.";
RL   Biochem. Biophys. Res. Commun. 358:920-924(2007).
RN   [6]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=17825049; DOI=10.1111/j.1365-2443.2007.01108.x;
RA   Sasagawa Y., Yamanaka K., Ogura T.;
RT   "ER E3 ubiquitin ligase HRD-1 and its specific partner chaperone BiP play
RT   important roles in ERAD and developmental growth in Caenorhabditis
RT   elegans.";
RL   Genes Cells 12:1063-1073(2007).
RN   [7]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=18097415; DOI=10.1038/nature06388;
RA   Ramadan K., Bruderer R., Spiga F.M., Popp O., Baur T., Gotta M.,
RA   Meyer H.H.;
RT   "Cdc48/p97 promotes reformation of the nucleus by extracting the kinase
RT   Aurora B from chromatin.";
RL   Nature 450:1258-1262(2007).
RN   [8]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH UNC-45; UFD-2 AND CHN-1,
RP   INTERACTION WITH CDC-48.2 AND UFD-2, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, DEVELOPMENTAL STAGE, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF
RP   804-ASP--ASN-809.
RX   PubMed=17369820; DOI=10.1038/ncb1554;
RA   Janiesch P.C., Kim J., Mouysset J., Barikbin R., Lochmueller H.,
RA   Cassata G., Krause S., Hoppe T.;
RT   "The ubiquitin-selective chaperone CDC-48/p97 links myosin assembly to
RT   human myopathy.";
RL   Nat. Cell Biol. 9:379-390(2007).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, LACK OF INTERACTION WITH AIR-2, AND
RP   DISRUPTION PHENOTYPE.
RX   PubMed=18854144; DOI=10.1016/j.devcel.2008.08.005;
RA   Heallen T.R., Adams H.P., Furuta T., Verbrugghe K.J., Schumacher J.M.;
RT   "An Afg2/Spaf-related Cdc48-like AAA ATPase regulates the stability and
RT   activity of the C. elegans Aurora B kinase AIR-2.";
RL   Dev. Cell 15:603-616(2008).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND MUTAGENESIS
RP   OF LYS-257 AND LYS-530.
RX   PubMed=18782221; DOI=10.1111/j.1365-2443.2008.01214.x;
RA   Nishikori S., Yamanaka K., Sakurai T., Esaki M., Ogura T.;
RT   "p97 Homologs from Caenorhabditis elegans, CDC-48.1 and CDC-48.2, suppress
RT   the aggregate formation of huntingtin exon1 containing expanded polyQ
RT   repeat.";
RL   Genes Cells 13:827-838(2008).
RN   [11]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH HIM-6 AND CRP-1, INTERACTION
RP   WITH HIM-6 AND CRP-1, AND DISRUPTION PHENOTYPE.
RX   PubMed=18458060; DOI=10.1128/mcb.02252-07;
RA   Caruso M.E., Jenna S., Bouchecareilh M., Baillie D.L., Boismenu D.,
RA   Halawani D., Latterich M., Chevet E.;
RT   "GTPase-mediated regulation of the unfolded protein response in
RT   Caenorhabditis elegans is dependent on the AAA+ ATPase CDC-48.";
RL   Mol. Cell. Biol. 28:4261-4274(2008).
RN   [12]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=18728180; DOI=10.1073/pnas.0805944105;
RA   Mouysset J., Deichsel A., Moser S., Hoege C., Hyman A.A., Gartner A.,
RA   Hoppe T.;
RT   "Cell cycle progression requires the CDC-48UFD-1/NPL-4 complex for
RT   efficient DNA replication.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12879-12884(2008).
RN   [13]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH ATX-3 AND UBXN-5, AND
RP   INTERACTION WITH ATX-3 AND UBXN-5.
RX   PubMed=19545544; DOI=10.1016/j.bbrc.2009.06.092;
RA   Rodrigues A.J., Neves-Carvalho A., Ferro A., Rokka A., Corthals G.,
RA   Logarinho E., Maciel P.;
RT   "ATX-3, CDC-48 and UBXN-5: a new trimolecular complex in Caenorhabditis
RT   elegans.";
RL   Biochem. Biophys. Res. Commun. 386:575-581(2009).
RN   [14]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=19773360; DOI=10.1242/jcs.052415;
RA   Sasagawa Y., Otani M., Higashitani N., Higashitani A., Sato K., Ogura T.,
RA   Yamanaka K.;
RT   "Caenorhabditis elegans p97 controls germline-specific sex determination by
RT   controlling the TRA-1 level in a CUL-2-dependent manner.";
RL   J. Cell Sci. 122:3663-3672(2009).
RN   [15]
RP   IDENTIFICATION IN A COMPLEX WITH UBXN-3; UFD-1 AND NPL-4.1, INTERACTION
RP   WITH UBXN-1; UBXN-2; UBXN-3; UBXN-4; UBXN-6 AND UFD-1, SUBCELLULAR
RP   LOCATION, AND DISRUPTION PHENOTYPE.
RX   PubMed=20977550; DOI=10.1111/j.1365-2443.2010.01454.x;
RA   Sasagawa Y., Yamanaka K., Saito-Sasagawa Y., Ogura T.;
RT   "Caenorhabditis elegans UBX cofactors for CDC-48/p97 control
RT   spermatogenesis.";
RL   Genes Cells 15:1201-1215(2010).
RN   [16]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF LYS-257; GLU-311; ASN-354; ARG-365; PRO-467; ARG-471;
RP   LYS-530; GLU-584; ASN-631 AND ARG-642.
RX   PubMed=21454554; DOI=10.1074/jbc.m110.201400;
RA   Nishikori S., Esaki M., Yamanaka K., Sugimoto S., Ogura T.;
RT   "Positive cooperativity of the p97 AAA ATPase is critical for essential
RT   functions.";
RL   J. Biol. Chem. 286:15815-15820(2011).
RN   [17]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=21981920; DOI=10.1016/j.molcel.2011.08.028;
RA   Franz A., Orth M., Pirson P.A., Sonneville R., Blow J.J., Gartner A.,
RA   Stemmann O., Hoppe T.;
RT   "CDC-48/p97 coordinates CDT-1 degradation with GINS chromatin dissociation
RT   to ensure faithful DNA replication.";
RL   Mol. Cell 44:85-96(2011).
RN   [18]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH ATX-3 AND UFD-2, INTERACTION
RP   WITH ATX-3 AND UFD-2, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF
RP   804-ASP--ASN-809.
RX   PubMed=21317884; DOI=10.1038/ncb2200;
RA   Kuhlbrodt K., Janiesch P.C., Kevei E., Segref A., Barikbin R., Hoppe T.;
RT   "The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and
RT   proteostasis.";
RL   Nat. Cell Biol. 13:273-281(2011).
RN   [19]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=22768338; DOI=10.1371/journal.pone.0040145;
RA   Miedel M.T., Graf N.J., Stephen K.E., Long O.S., Pak S.C., Perlmutter D.H.,
RA   Silverman G.A., Luke C.J.;
RT   "A pro-cathepsin L mutant is a luminal substrate for endoplasmic-reticulum-
RT   associated degradation in C. elegans.";
RL   PLoS ONE 7:E40145-E40145(2012).
RN   [20]
RP   INTERACTION WITH UBXN-2.
RX   PubMed=23649807; DOI=10.1083/jcb.201209107;
RA   Kress E., Schwager F., Holtackers R., Seiler J., Prodon F., Zanin E.,
RA   Eiteneuer A., Toya M., Sugimoto A., Meyer H., Meraldi P., Gotta M.;
RT   "The UBXN-2/p37/p47 adaptors of CDC-48/p97 regulate mitosis by limiting the
RT   centrosomal recruitment of Aurora A.";
RL   J. Cell Biol. 201:559-575(2013).
RN   [21]
RP   ACTIVITY REGULATION, SUBUNIT, AND MUTAGENESIS OF LYS-530 AND GLU-584.
RX   PubMed=24055316; DOI=10.1016/j.str.2013.08.017;
RA   Noi K., Yamamoto D., Nishikori S., Arita-Morioka K., Kato T., Ando T.,
RA   Ogura T.;
RT   "High-speed atomic force microscopic observation of ATP-dependent rotation
RT   of the AAA+ chaperone p97.";
RL   Structure 21:1992-2002(2013).
RN   [22]
RP   INTERACTION WITH UFD-3 AND CDC-48.2, AND SUBCELLULAR LOCATION.
RX   PubMed=25721663; DOI=10.1016/j.bbrc.2015.02.088;
RA   Murayama Y., Ogura T., Yamanaka K.;
RT   "Characterization of C-terminal adaptors, UFD-2 and UFD-3, of CDC-48 on the
RT   polyglutamine aggregation in C. elegans.";
RL   Biochem. Biophys. Res. Commun. 459:154-160(2015).
RN   [23]
RP   FUNCTION.
RX   PubMed=25652260; DOI=10.15252/embr.201439123;
RA   Marza E., Taouji S., Barroso K., Raymond A.A., Guignard L., Bonneu M.,
RA   Pallares-Lupon N., Dupuy J.W., Fernandez-Zapico M.E., Rosenbaum J.,
RA   Palladino F., Dupuy D., Chevet E.;
RT   "Genome-wide screen identifies a novel p97/CDC-48-dependent pathway
RT   regulating ER-stress-induced gene transcription.";
RL   EMBO Rep. 16:332-340(2015).
RN   [24]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH UBXN-3 AND CDT-1, INTERACTION
RP   WITH UBXN-3 AND CDT-1, AND DISRUPTION PHENOTYPE.
RX   PubMed=26842564; DOI=10.1038/ncomms10612;
RA   Franz A., Pirson P.A., Pilger D., Halder S., Achuthankutty D., Kashkar H.,
RA   Ramadan K., Hoppe T.;
RT   "Chromatin-associated degradation is defined by UBXN-3/FAF1 to safeguard
RT   DNA replication fork progression.";
RL   Nat. Commun. 7:10612-10612(2016).
RN   [25]
RP   INTERACTION WITH UFD-2.
RX   PubMed=27669035; DOI=10.1038/nsmb.3296;
RA   Ackermann L., Schell M., Pokrzywa W., Kevei E., Gartner A., Schumacher B.,
RA   Hoppe T.;
RT   "E4 ligase-specific ubiquitination hubs coordinate DNA double-strand-break
RT   repair and apoptosis.";
RL   Nat. Struct. Mol. Biol. 23:995-1002(2016).
RN   [26]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=28368371; DOI=10.1038/ncb3500;
RA   Sonneville R., Moreno S.P., Knebel A., Johnson C., Hastie C.J., Gartner A.,
RA   Gambus A., Labib K.;
RT   "CUL-2LRR-1 and UBXN-3 drive replisome disassembly during DNA replication
RT   termination and mitosis.";
RL   Nat. Cell Biol. 19:468-479(2017).
CC   -!- FUNCTION: ATP-dependent chaperone which probably uses the energy
CC       provided by ATP hydrolysis to generate mechanical force to unfold
CC       substrate proteins, disassemble protein complexes, and disaggregate
CC       protein aggregates (PubMed:18782221, PubMed:18854144, PubMed:22768338).
CC       Can also prevent aggregation of unfolded proteins also in an ATP-
CC       independent manner (PubMed:18782221). Targets polyubiquitinated
CC       proteins for proteasomal degradation by binding to 'Lys-48'-linked
CC       polyubiquitin chains (PubMed:19545544). Involved in the cytoplasmic
CC       elimination of misfolded proteins exported from the ER
CC       (PubMed:16647269, PubMed:17825049, PubMed:21317884, PubMed:22768338,
CC       PubMed:25652260). This pathway, known as ERAD, prevents the activation
CC       of the unfolded protein response (UPR) caused by the accumulation of
CC       misfolded proteins in the ER (PubMed:16647269, PubMed:17825049,
CC       PubMed:21317884, PubMed:22768338, PubMed:25652260). In association with
CC       helicase him-6 and GTPase crp-1, regulates the unfolded protein
CC       response (UPR) following ER stress, probably independently of the ERAD
CC       pathway (PubMed:18458060). Together with udf-2 and chn-1, regulates
CC       myosin assembly in body wall muscles by targeting myosin chaperone unc-
CC       45 for proteasomal degradation (PubMed:17369820). Together with the
CC       ufd-1-npl-4 complex, controls the switch from spermatogenesis to
CC       oogenesis by regulating E3 ligase cul-2 complex-mediated tra-1
CC       proteasomal degradation (PubMed:19773360). During oocyte meiosis and
CC       together with cdc-48.2, required for chromosome condensation at the
CC       diakinesis phase in prophase I and for progression of metaphase I
CC       (PubMed:17512499). During the first embryonic cell division, regulates
CC       DNA replication and thus chromosome segregation and decondensation, and
CC       nuclear envelope re-assembly (PubMed:18097415, PubMed:18728180,
CC       PubMed:18854144, PubMed:21981920, PubMed:26842564, PubMed:28368371). In
CC       S phase and in association with ufd-1, npl-4.1 and/or npl-4.2 and ubxn-
CC       3, ensures the degradation of DNA licensing factor cdt-1 after the
CC       initiation of DNA replication and thus the disassembly of the DNA
CC       replication CMG helicase complex by promoting the dissociation from
CC       chromatin of several of its components including cdc-45 and sld-5
CC       (PubMed:21981920, PubMed:26842564, PubMed:28368371). Regulates ubxn-3
CC       nuclear localization during S phase (PubMed:26842564). During the first
CC       embryonic cell divisions and together with cdc-48.2, regulates the re-
CC       assembly of the nuclear envelope after mitosis possibly by inactivating
CC       kinase air-2, a component of the chromosomal passenger complex (CPC)
CC       (PubMed:18097415). However, in another study, cdc-48.1 does not appear
CC       to be implicated in the regulation of air-2 (PubMed:18854144).
CC       {ECO:0000269|PubMed:16647269, ECO:0000269|PubMed:17369820,
CC       ECO:0000269|PubMed:17512499, ECO:0000269|PubMed:17825049,
CC       ECO:0000269|PubMed:18097415, ECO:0000269|PubMed:18458060,
CC       ECO:0000269|PubMed:18728180, ECO:0000269|PubMed:18782221,
CC       ECO:0000269|PubMed:18854144, ECO:0000269|PubMed:19545544,
CC       ECO:0000269|PubMed:19773360, ECO:0000269|PubMed:21317884,
CC       ECO:0000269|PubMed:21981920, ECO:0000269|PubMed:22768338,
CC       ECO:0000269|PubMed:25652260, ECO:0000269|PubMed:26842564,
CC       ECO:0000269|PubMed:28368371}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.6;
CC         Evidence={ECO:0000269|PubMed:18782221, ECO:0000269|PubMed:18854144,
CC         ECO:0000269|PubMed:21454554};
CC   -!- ACTIVITY REGULATION: The first ATP-binding region has low ATPase
CC       activity (PubMed:21454554). The second ATP-binding region is
CC       responsible for ATPase activity (PubMed:21454554). ATP binding to the
CC       first ATP-binding region induces intrinsic activity of the second ATP-
CC       binding region (PubMed:21454554). While ATP binding to the first ATP-
CC       binding region appears to prevent ATP hydrolysis by the second ATP-
CC       binding region, ADP-binding to first region promotes the coordinate and
CC       cooperative ATPase cycle of the second ATP-binding region
CC       (PubMed:21454554). ATP binding to the first ATP-binding region induces
CC       a conformational change, promoting the rotation of the first ATP-
CC       binding region relative to the second ATP-binding region in the hexamer
CC       (PubMed:24055316). Inhibited by N-ethylmaleimide (NEM)
CC       (PubMed:18782221). {ECO:0000269|PubMed:18782221,
CC       ECO:0000269|PubMed:21454554, ECO:0000269|PubMed:24055316}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.39 mM for ATP (at 30 degrees Celsius)
CC         {ECO:0000269|PubMed:21454554};
CC   -!- SUBUNIT: Homohexamer; oligomerization is ATP-independent
CC       (PubMed:18782221, PubMed:24055316). Forms a ring-shaped particle of
CC       18.3 nm diameter, that displays 6-fold radial symmetry
CC       (PubMed:24055316). Interacts with cdc-48.2 and thus may form
CC       heterohexamers (PubMed:16647269, PubMed:17369820, PubMed:25721663).
CC       Forms a complex composed of cdc-48.1, him-6 and crp-1; within the
CC       complex, interacts with helicase him-6 and GTPase crp-1
CC       (PubMed:18458060). Forms a complex composed of deubiquitinating enzyme
CC       atx-3, adapter ubxn-5 and cdc-48.1; within the complex, interacts (via
CC       N-terminus) with ubxn-5 and with atx-3 (PubMed:19545544). Forms a
CC       complex composed of deubiquitinating enzyme atx-3, E4 ubiquitin-protein
CC       ligase ufd-2 and cdc-48.1; within the complex, interacts with atx-3 and
CC       (via DDDLYN motif) with ufd-2 (PubMed:21317884, PubMed:27669035).
CC       Interacts (via N-terminus) with atx-3 (via RRDR motif); the interaction
CC       is not required for atx-3 enzymatic activity (PubMed:19545544,
CC       PubMed:21317884). Forms a complex composed of cdc-48.1, myosin
CC       chaperone unc-45, ubiquitin-protein ligases ufd-2 and chn-1; within the
CC       complex, interacts (via DDDLYN motif) with ufd-2 and targets myosin
CC       chaperone unc-45 for proteasomal degradation (PubMed:17369820,
CC       PubMed:27669035). Forms a complex composed of ubxn-3, ufd-1, npl-4.1
CC       and cdc-48.1; within the complex, interacts (via N-terminus) with ubxn-
CC       3 (via FPK motif) and with ufd-1 (PubMed:16647269, PubMed:20977550).
CC       Forms a complex composed of ubxn-3, cdc-48.1 and/or cdc-48.2 and
CC       substrate cdt-1 (PubMed:26842564). Interacts (via N-terminus) with
CC       ubxn-1 (PubMed:16647269, PubMed:20977550). Interacts (via N-terminus)
CC       with ubxn-2 (PubMed:20977550, PubMed:23649807). Interacts (via N-
CC       terminus) with ubxn-4 (PubMed:20977550). Interacts with ubxn-6
CC       (PubMed:20977550). Interacts with ufd-3 (PubMed:25721663). Does not
CC       interact with air-2 (PubMed:18854144). {ECO:0000269|PubMed:16647269,
CC       ECO:0000269|PubMed:17369820, ECO:0000269|PubMed:18458060,
CC       ECO:0000269|PubMed:18782221, ECO:0000269|PubMed:18854144,
CC       ECO:0000269|PubMed:19545544, ECO:0000269|PubMed:20977550,
CC       ECO:0000269|PubMed:21317884, ECO:0000269|PubMed:23649807,
CC       ECO:0000269|PubMed:24055316, ECO:0000269|PubMed:25721663,
CC       ECO:0000269|PubMed:26842564, ECO:0000269|PubMed:27669035}.
CC   -!- INTERACTION:
CC       P54811; P54811: cdc-48.1; NbExp=2; IntAct=EBI-320245, EBI-320245;
CC       P54811; P54812: cdc-48.2; NbExp=6; IntAct=EBI-320245, EBI-320265;
CC       P54811; Q9TXH9: ubxn-1; NbExp=3; IntAct=EBI-320245, EBI-320236;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:20977550, ECO:0000269|PubMed:25721663}. Cytoplasm
CC       {ECO:0000269|PubMed:17369820}. Note=Colocalizes with ubxn-1, ubxn-2 and
CC       ubxn-3 to the perinuclear region in spermatocytes (PubMed:20977550).
CC       Localizes to the perinuclear region in intestinal cells
CC       (PubMed:25721663). {ECO:0000269|PubMed:20977550,
CC       ECO:0000269|PubMed:25721663}.
CC   -!- TISSUE SPECIFICITY: Expressed in germ cells and spermatheca
CC       (PubMed:16701565). Expressed in body wall muscles (PubMed:17369820).
CC       {ECO:0000269|PubMed:16701565, ECO:0000269|PubMed:17369820}.
CC   -!- DEVELOPMENTAL STAGE: Expressed highly in embryos (at protein level)
CC       (PubMed:16701565, PubMed:17369820). Expression decreases in larvae and
CC       increases again in adults (at protein level) (PubMed:16701565,
CC       PubMed:17369820). At the L4 larval stage, expressed in the proximal
CC       gonad, predominantly at the pachytene stage and in spermatocytes
CC       (PubMed:19773360). Not expressed in sperm (PubMed:19773360).
CC       {ECO:0000269|PubMed:16701565, ECO:0000269|PubMed:17369820,
CC       ECO:0000269|PubMed:19773360}.
CC   -!- INDUCTION: Induced upon ER stress. Repressed by starvation and
CC       oxidative stress. {ECO:0000269|PubMed:16701565}.
CC   -!- DISRUPTION PHENOTYPE: RNAi-mediated knockdown causes partial embryonic
CC       lethality (PubMed:15716356, PubMed:18854144). Impairs response to ER
CC       stress (PubMed:18458060). Abnormal accumulation of myosin chaperone
CC       unc-45 in body wall muscles (PubMed:17369820). RNAi-mediated knockdown
CC       in an unc-45 (m94) mutant background, restores motility
CC       (PubMed:17369820). Simultaneous RNAi-mediated knockdown of cdc-48.2 in
CC       embryos causes embryonic lethality (PubMed:15716356, PubMed:16647269,
CC       PubMed:18097415, PubMed:18728180, PubMed:18854144). Defects in oocyte
CC       meiosis I progression (PubMed:17512499). Defects in embryo S phase DNA
CC       replication causing delays in cell cycle progression (PubMed:17512499,
CC       PubMed:18728180, PubMed:21981920, PubMed:26842564, PubMed:28368371). At
CC       the end of mitosis, impairs chromatin decondensation and nuclear
CC       envelope re-assembly (PubMed:18097415, PubMed:18728180,
CC       PubMed:18854144). In addition, abnormal accumulation of air-2 on
CC       mitotic chromatin and impaired air-2 activation (PubMed:18097415). Does
CC       not affect ER transition into sheet-like structures at the onset of
CC       embryonic mitosis (PubMed:15716356). Simultaneous RNAi-mediated
CC       knockdown of cdc-48.2 in young adults decreases lifespan, induces the
CC       unfolded protein response, increases overall levels of
CC       polyubiquitinated proteins, and impairs the degradation of misfolded ER
CC       proteins (PubMed:16647269, PubMed:17369820, PubMed:17825049,
CC       PubMed:21317884, PubMed:22768338). Causes defects in germline
CC       development (PubMed:20977550). In an atx-3 (gk193) mutant background,
CC       causes a 50 percent increase in longevity, a delay in age-related
CC       muscle degeneration and resistance to oxidative and heat stresses
CC       (PubMed:21317884). {ECO:0000269|PubMed:15716356,
CC       ECO:0000269|PubMed:16647269, ECO:0000269|PubMed:17369820,
CC       ECO:0000269|PubMed:17512499, ECO:0000269|PubMed:17825049,
CC       ECO:0000269|PubMed:18097415, ECO:0000269|PubMed:18458060,
CC       ECO:0000269|PubMed:18728180, ECO:0000269|PubMed:18854144,
CC       ECO:0000269|PubMed:20977550, ECO:0000269|PubMed:21317884,
CC       ECO:0000269|PubMed:21981920, ECO:0000269|PubMed:22768338,
CC       ECO:0000269|PubMed:26842564, ECO:0000269|PubMed:28368371}.
CC   -!- SIMILARITY: Belongs to the AAA ATPase family. CDC48 subfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: The role of cdc-48.1 in the regulation of kinase air-2, a
CC       component of the chromosomal passenger complex (CPC), is controversial.
CC       One study suggests that cdc-48.1 inactivates air-2 at the end of
CC       mitosis whereas a second study shows that cdc-48.1 is not implicated in
CC       the regulation of air-2. {ECO:0000269|PubMed:18097415,
CC       ECO:0000269|PubMed:18854144}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z49886; CAA90050.1; -; Genomic_DNA.
DR   PIR; T18970; T18970.
DR   RefSeq; NP_496273.1; NM_063872.6.
DR   AlphaFoldDB; P54811; -.
DR   SMR; P54811; -.
DR   BioGRID; 39940; 39.
DR   DIP; DIP-26650N; -.
DR   FunCoup; P54811; 2522.
DR   IntAct; P54811; 8.
DR   STRING; 6239.C06A1.1.1; -.
DR   PaxDb; 6239-C06A1.1; -.
DR   PeptideAtlas; P54811; -.
DR   EnsemblMetazoa; C06A1.1.1; C06A1.1.1; WBGene00007352.
DR   GeneID; 174624; -.
DR   KEGG; cel:CELE_C06A1.1; -.
DR   UCSC; C06A1.1.1; c. elegans.
DR   AGR; WB:WBGene00007352; -.
DR   CTD; 174624; -.
DR   WormBase; C06A1.1; CE02114; WBGene00007352; cdc-48.1.
DR   eggNOG; KOG0730; Eukaryota.
DR   GeneTree; ENSGT00970000196377; -.
DR   HOGENOM; CLU_000688_12_3_1; -.
DR   InParanoid; P54811; -.
DR   OMA; VWPAYPE; -.
DR   OrthoDB; 27435at2759; -.
DR   PhylomeDB; P54811; -.
DR   PRO; PR:P54811; -.
DR   Proteomes; UP000001940; Chromosome II.
DR   Bgee; WBGene00007352; Expressed in adult organism and 3 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:WormBase.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:WormBase.
DR   GO; GO:0005634; C:nucleus; IDA:WormBase.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:WormBase.
DR   GO; GO:0034098; C:VCP-NPL4-UFD1 AAA ATPase complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:WormBase.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0031593; F:polyubiquitin modification-dependent protein binding; IBA:GO_Central.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0097352; P:autophagosome maturation; IBA:GO_Central.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; IGI:WormBase.
DR   GO; GO:0036503; P:ERAD pathway; IGI:WormBase.
DR   GO; GO:0051228; P:mitotic spindle disassembly; IBA:GO_Central.
DR   GO; GO:0045977; P:positive regulation of mitotic cell cycle, embryonic; IGI:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:1905634; P:regulation of protein localization to chromatin; IGI:UniProtKB.
DR   GO; GO:0030970; P:retrograde protein transport, ER to cytosol; IBA:GO_Central.
DR   CDD; cd19519; RecA-like_CDC48_r1-like; 1.
DR   CDD; cd19528; RecA-like_CDC48_r2-like; 1.
DR   FunFam; 1.10.8.60:FF:000004; Cell division control 48; 1.
DR   FunFam; 3.10.330.10:FF:000001; Cell division control 48; 1.
DR   FunFam; 2.40.40.20:FF:000003; Transitional endoplasmic reticulum ATPase; 1.
DR   FunFam; 3.40.50.300:FF:000012; Transitional endoplasmic reticulum ATPase; 1.
DR   FunFam; 3.40.50.300:FF:000048; Transitional endoplasmic reticulum ATPase; 1.
DR   Gene3D; 1.10.8.60; -; 1.
DR   Gene3D; 2.40.40.20; -; 1.
DR   Gene3D; 3.10.330.10; -; 1.
DR   Gene3D; 6.10.20.150; -; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR005938; AAA_ATPase_CDC48.
DR   InterPro; IPR050168; AAA_ATPase_domain.
DR   InterPro; IPR041569; AAA_lid_3.
DR   InterPro; IPR009010; Asp_de-COase-like_dom_sf.
DR   InterPro; IPR003959; ATPase_AAA_core.
DR   InterPro; IPR003960; ATPase_AAA_CS.
DR   InterPro; IPR004201; Cdc48_dom2.
DR   InterPro; IPR029067; CDC48_domain_2-like_sf.
DR   InterPro; IPR003338; CDC4_N-term_subdom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR015415; Spast_Vps4_C.
DR   NCBIfam; TIGR01243; CDC48; 1.
DR   PANTHER; PTHR23077; AAA-FAMILY ATPASE; 1.
DR   PANTHER; PTHR23077:SF52; TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE HOMOLOG 1; 1.
DR   Pfam; PF00004; AAA; 2.
DR   Pfam; PF17862; AAA_lid_3; 2.
DR   Pfam; PF02933; CDC48_2; 1.
DR   Pfam; PF02359; CDC48_N; 1.
DR   Pfam; PF09336; Vps4_C; 1.
DR   SMART; SM00382; AAA; 2.
DR   SMART; SM01072; CDC48_2; 1.
DR   SMART; SM01073; CDC48_N; 1.
DR   SUPFAM; SSF50692; ADC-like; 1.
DR   SUPFAM; SSF54585; Cdc48 domain 2-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2.
DR   PROSITE; PS00674; AAA; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Chaperone; Cytoplasm; Hydrolase; Nucleotide-binding;
KW   Reference proteome; Repeat.
FT   CHAIN           1..809
FT                   /note="Transitional endoplasmic reticulum ATPase homolog 1"
FT                   /id="PRO_0000084577"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          779..809
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          803..809
FT                   /note="Interaction with ufd-2"
FT                   /evidence="ECO:0000269|PubMed:17369820,
FT                   ECO:0000269|PubMed:21317884"
FT   COMPBIAS        8..21
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         253..259
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P55072"
FT   BINDING         354
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P55072"
FT   BINDING         390
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P55072"
FT   BINDING         527..532
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q01853"
FT   MUTAGEN         257
FT                   /note="K->A: Loss of ATP binding. Complete loss of
FT                   catalytic activity. Complete loss of catalytic activity
FT                   without affecting oligomerization; when associated with
FT                   A-365 and A-530."
FT                   /evidence="ECO:0000269|PubMed:18782221,
FT                   ECO:0000269|PubMed:21454554"
FT   MUTAGEN         257
FT                   /note="K->T: Loss of ATP binding. Complete loss of
FT                   catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         311
FT                   /note="E->D: Severe loss of ATP hydrolysis without
FT                   affecting ATP binding."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         311
FT                   /note="E->N,A: Severe loss of ATP hydrolysis without
FT                   affecting ATP binding and moderate reduction in
FT                   cooperativity between the 2 ATP-binding regions."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         311
FT                   /note="E->Q: Severe loss of ATP hydrolysis without
FT                   affecting ATP binding and loss of cooperativity between the
FT                   2 ATP-binding regions. Slight reduction in catalytic
FT                   activity; when associated with A-354, A-365, A-467, S-467
FT                   or P-467. Complete loss of catalytic activity; when
FT                   associated with Q-584. Restores normal catalytic activity;
FT                   when associated with H-471."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         354
FT                   /note="N->A: Slight reduction in catalytic activity. Slight
FT                   reduction in catalytic activity; when associated with
FT                   Q-311. Complete loss of catalytic activity; when associated
FT                   with A-631."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         365
FT                   /note="R->A: Slight reduction in catalytic activity. Slight
FT                   reduction in catalytic activity; when associated with
FT                   Q-311. Complete loss of catalytic activity; when associated
FT                   with A-257 or A-642. Does not affect oligomerization; when
FT                   associated with A-257."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         467
FT                   /note="P->A,S: Slight reduction in catalytic activity; when
FT                   associated with Q-311."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         471
FT                   /note="R->H: Restores normal catalytic activity; when
FT                   associated with Q-311."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         530
FT                   /note="K->A: Loss of ATP binding and impaired rotation
FT                   between the two ATP-binding regions in the hexamer.
FT                   Complete loss of catalytic activity. Complete loss of
FT                   catalytic activity without affecting oligomerization; when
FT                   associated with A-257."
FT                   /evidence="ECO:0000269|PubMed:18782221,
FT                   ECO:0000269|PubMed:21454554, ECO:0000269|PubMed:24055316"
FT   MUTAGEN         530
FT                   /note="K->T: Complete loss of catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         584
FT                   /note="E->D: Severe loss of ATP hydrolysis without
FT                   affecting ATP binding."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         584
FT                   /note="E->Q: Severe loss of ATP hydrolysis without
FT                   affecting ATP binding. Does not affect rotation between the
FT                   2 ATP-binding regions in the hexamer in presence of ATP or
FT                   ADP. Complete loss of catalytic activity; when associated
FT                   with Q-311."
FT                   /evidence="ECO:0000269|PubMed:21454554,
FT                   ECO:0000269|PubMed:24055316"
FT   MUTAGEN         631
FT                   /note="N->A: Severe reduction in catalytic activity.
FT                   Complete loss of catalytic activity; when associated with
FT                   A-354."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         642
FT                   /note="R->A: Severe reduction in catalytic activity.
FT                   Complete loss of catalytic activity; when associated with
FT                   A-365."
FT                   /evidence="ECO:0000269|PubMed:21454554"
FT   MUTAGEN         804..809
FT                   /note="Missing: Loss of interaction with ufd-2 but not with
FT                   atx-3."
FT                   /evidence="ECO:0000269|PubMed:17369820,
FT                   ECO:0000269|PubMed:21317884"
SQ   SEQUENCE   809 AA;  89785 MW;  ECF02EF8B939A777 CRC64;
     MASVPTHQSE KEKKNDELST AILKDKVKPN RLIVDQSEQD DNSVIAVSQA KMDELGLFRG
     DAVILKGKKR KESVAIIVSD ESCPNEKVRM NRVVRNNLRI RLGDVVSITP APNLSYGTRI
     HVLPIDDTIE GLTGNLFDVF LKPYFLEAYR PLHKGDIFTV QAAMRTVEFK VVETEPAPAC
     IVSPDTMIHY EGDPIKREEE EESMNDIGYD DLGGVRKQLA QIKEMVELPL RHPQLFKAIG
     IKPPRGILLF GPPGTGKTLI ARAVANETGS FFFLINGPEV MSKMSGESES NLRKAFEECE
     KNQPAILFID EIDAIAPKRE KTNGEVERRI VSQLLTLMDG VKGRSNLVVI AATNRPNSID
     GALRRFGRFD REIDIGIPDA VGRLEILRIH TKNMKLADDV DLEQIANECH GFVGADLASL
     CSEAALQQIR EKMELIDLED DQIDAEVLNS LAVTMENFRF AQGKSSPSAL REAVVETPNT
     TWSDIGGLQN VKRELQELVQ YPVEHPEKYL KFGMQPSRGV LFYGPPGCGK TLLAKAIANE
     CQANFISIKG PELLTMWFGE SEANVRDVFD KARAAAPCVL FFDELDSIAK ARGGGAGGDG
     GGASDRVINQ VLTEMDGMNA KKNVFIIGAT NRPDIIDPAV LRPGRLDQLI YIPLPDEASR
     HQILKASLRK TPLSKDLDLT FLAKNTVGFS GADLTEICQR ACKLAIRESI EKEIRIEKER
     QDRQARGEEL MEDDAVDPVP EITRAHFEEA MKFARRSVTD NDIRKYEMFA QTLQQSRGFG
     NNFKFPGEQR GSDAPSAPVP AQDDDDLYN
//
